<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936234</url>
  </required_header>
  <id_info>
    <org_study_id>FINNjA-DM</org_study_id>
    <nct_id>NCT00936234</nct_id>
  </id_info>
  <brief_title>Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).</brief_title>
  <acronym>FINNjA-DM</acronym>
  <official_title>Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SDF-1, an important cytokine for neovascularisation is cleaved by (dipeptidyl peptidase IV)&#xD;
      DPPIV.&#xD;
&#xD;
      The aim of this study is to assess the effect of the dipeptidyl peptidase IV inhibitor&#xD;
      vildagliptin (GalvusÂ®) on endothelial function as well as number and functional activity of&#xD;
      progenitor cells in patients with documented diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The peptidase CD26 (DPPIV/dipeptidyl peptidase IV) removes dipeptides from the amino terminus&#xD;
      of proteins and thereby inactivates these cleaved proteins. It was shown, that CD26 cleaves&#xD;
      SDF-1 into a non-mitogenic molecule. Inhibition or deletion of CD26 leads to an increased&#xD;
      homing of hematopoietic progenitor cells to the bone marrow after transplantation by&#xD;
      increasing the invasion capacity of these cells {Campbell et al. 2008; Christopherson et al.&#xD;
      2004}.&#xD;
&#xD;
      The cytokine SDF-1 is released in response to hypoxia, is crucial for progenitor cell homing&#xD;
      and recruitment of cells for neovascularisation. Invasion capacity is closely related to the&#xD;
      cytokine SDF-1 and the SDF-1 receptor CXCR4 {Ceradini et al. 2004}. The in vivo&#xD;
      neovascularisation capacity of progenitor cells is closely correlated to their functional&#xD;
      capacity as SDF-1 induced invasion or colony-forming capacity {Heeschen et al. 2004; Britten&#xD;
      et al. 2003; Assmus et al. 2007}.&#xD;
&#xD;
      Therefore, the aim of this study is to assess the effect of the dipeptidyl peptidase IV&#xD;
      inhibitor vildagliptin on endothelial function as well as number and functional activity of&#xD;
      progenitor cells in patients with documented diabetes mellitus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    insufficient recruitment&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Function of Progenitor Cells</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors</condition>
  <arm_group>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>starting with vildagliptin for 30 days followed by placebo for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>starting with placebo for 30 days followed by vildagliptin for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vildagliptin</arm_group_label>
    <other_name>Galvus (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diabetes mellitus type 2 under stable medication&#xD;
&#xD;
          -  HbA1c between 7% an 10%&#xD;
&#xD;
          -  age between 18 and 80 years&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrillation (plethysmographic recordings can only obtained in sinus-rhythm)&#xD;
&#xD;
          -  CAD with reduced left ventricular ejection fraction (LVEF &lt;45%)&#xD;
&#xD;
          -  Pregnancy, chronic or acute infection, fever&#xD;
&#xD;
          -  Diabetes mellitus type 1&#xD;
&#xD;
          -  Newly diagnosed diabetes, uncontrolled diabetes&#xD;
&#xD;
          -  Neoplasm&#xD;
&#xD;
          -  Known allergy to study drug&#xD;
&#xD;
          -  Severe liver/kidney disease&#xD;
&#xD;
          -  HIV, Hepatitis&#xD;
&#xD;
          -  Participation at other studies within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas M. Zeiher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology, University of Frankfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Florian Seeger</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>CAD</keyword>
  <keyword>diabetes</keyword>
  <keyword>SDF-1</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

